Thrombophilia work-up and clinical outcomes in Indian patients with unprovoked venous and arterial thrombosis aged 18-50 years

Harimadhavan, Monisha; Ram, Bharath; G, Karthick R; Shetty, Devi Prasad; Prabhu, Shilpa; S, Nataraj K; Nayak, Akshatha; Damodar, Sharat; Zanon, Ezio; Castaman, Giancarlo; Federici, Augusto Bramante; Mancuso, Maria Elisa; Pasut, Gianfranco; Tosetto, Alberto; Rocino, Angiola; Santoro, Rita Carlotta; Barcellona, Doris; Tripodi, Armando; Di Castelnuovo, Augusto; Persichillo, Mariarosaria; Candura, Fabio; Marchesini, Emanuela; Forni, Gian Luca; Gringeri, Alessandro; Gentilini, Ilaria; Tricoli, Mirko; Najjar, Osama; Teofili, Luciana

doi:10.4081/btvb..193

Reviews

All Items

A re-appraisal of thrombogenesis in COVID-19, seen as a multiple "Complex system"

Sergio Coccheri

https://doi.org/10.4081/btvb.2022.48

1992

PDF: 344

Addressing some challenges of congenital fibrinogen disorders in 2023 and beyond

Cristina Santoro, Alessandro Casini

https://doi.org/10.4081/btvb.2023.75

1507

PDF: 434

An ecological alliance against air pollution and cardiovascular disease

Pier Mannuccio Mannucci

https://doi.org/10.4081/btvb.2022.21

1980

PDF: 387

Anticoagulation in obese patients: challenges and strategies

Alice Lipari, Esmeralda Capristo, Antonietta Ferretti, Erica De Candia

https://doi.org/10.4081/btvb.2025.174

1790

PDF: 249

HTML: 181

XML: 73

Antithrombotic therapy in idiopathic infertility

Fabio Tumminello, Silvia Cardi, Corrado Lodigiani, Maria Elisa Mancuso

https://doi.org/10.4081/btvb.2024.126

2943

PDF: 636

Artificial intelligence and machine learning in hemostasis and thrombosis

Paolo Gresele

https://doi.org/10.4081/btvb.2023.105

3449

PDF: 693

Aspirin or low-molecular weight heparin for thromboprophylaxis after a fracture? That is the question

Giuseppe Camporese, Paolo Prandoni, Walter Ageno

https://doi.org/10.4081/btvb.2023.82

1147

PDF: 540

Bioequivalence of von Willebrand factor-containing concentrates: implications for the choice in patients with von Willebrand disease. A position paper from the Italian Association of Hemophilia Centers

Ezio Zanon, Giancarlo Castaman, Augusto Bramante Federici, Maria Elisa Mancuso, Gianfranco Pasut, Alberto Tosetto, Angiola Rocino, Rita Carlotta Santoro

https://doi.org/10.4081/btvb.2026.415

723

PDF: 225

HTML: 57

Blood platelets, prostaglandins and aspirin: a historical and personal rereading

Giovanni de Gaetano, Chiara Cerletti

https://doi.org/10.4081/btvb.2024.121

1786

PDF: 301

Cardiovascular risk in hormone replacement therapy

Doris Barcellona

https://doi.org/10.4081/btvb.2026.411

1006

PDF: 212

Distal deep vein thrombosis: is there a way out of this dark forest?

Matteo Guarascio, Gerardo Nicola Pititto, Alessia Abenante, Marco Paolo Donadini

https://doi.org/10.4081/btvb.2024.129

1378

PDF: 362

Factor XI inhibitors in adjunct to antiplatelet therapy: the ultimate dual-pathway inhibition?

Mattia Galli, C. Michael Gibson, Dominick J. Angiolillo

https://doi.org/10.4081/btvb.2023.90

1796

PDF: 621

From rare to aware: confronting Lemierre syndrome

Silvia Cardi, Filippo Catalani, Luca Valerio, Stefano Barco

https://doi.org/10.4081/btvb.2024.147

2303

PDF: 449

Hemostasis and the kidney: an unforeseen initial opportunity to create a small research group that grew into an institute

Carlamaria Zoja, Ariela Benigni, Giuseppe Remuzzi

https://doi.org/10.4081/btvb.2025.190

557

PDF: 125

Supplementary: 40

Inflammation, platelets and diabetes

Francesca Santilli, Paola Simeone, Rossella Liani

https://doi.org/10.4081/btvb.2023.77

1036

PDF: 392

New perspectives for prevention of the post-thrombotic syndrome

Paolo Prandoni

https://doi.org/10.4081/btvb.2022.20

2057

PDF: 544

Polycythemia vera and management of the thrombotic risk: an update

Massimo Franchini

https://doi.org/10.4081/btvb.2023.102

2481

PDF: 394

Recent advances in classic heparin-induced thrombocytopenia (HIT), autoimmune HIT, spontaneous HIT, and vaccine-induced immune thrombotic thrombocytopenia

Bianca Clerici, Mariangela Scavone, Gian Marco Podda

https://doi.org/10.4081/btvb.2024.127

2522

PDF: 672

Role of platelet autophagy in cardiovascular diseases

Luca D'Ambrosio, Maurizio Forte, Giacomo Frati, Sebastiano Sciarretta

https://doi.org/10.4081/btvb.2024.133

1393

PDF: 325

Stroke in women: anticoagulation in a complicated puzzle

Francesco Marongiu, Elvira Grandone, Silvia Marongiu, Antonella Mameli, Doris Barcellona

https://doi.org/10.4081/btvb.2024.137

1464

PDF: 350

The amazing genetic complexity of anucleated platelets

Loredana Bury, Paolo Gresele

https://doi.org/10.4081/btvb.2022.33

2349

PDF: 417

The changing landscape of treatment for acquired hemophilia A

Massimo Franchini, Daniele Focosi

https://doi.org/10.4081/btvb.2025.157

1737

PDF: 436

The evolution of hemostasis genetics: from monogenic disorders to complex traits. A historical perspective

Augusto Di Castelnuovo

https://doi.org/10.4081/btvb.2025.184

1241

PDF: 235

The evolving landscape of gene therapy for congenital severe hemophilia: a 2024 state of the art

Giovanni Di Minno, Gaia Spadarella, Ilenia Lorenza Calcaterra, Giancarlo Castaman, Paolo Simioni, Raimondo De Cristofaro, Cristina Santoro, Flora Peyvandi, Matteo Di Minno

https://doi.org/10.4081/btvb.2024.144

1518

PDF: 287

SUPPLEMENTARY MATERIAL: 143

The key to fibrinolysis and thrombolysis

Roger Lijnen, Désiré Collen

https://doi.org/10.4081/btvb.2025.368

1484

PDF: 245

HTML: 123

The new era of anticoagulation: factor XI and XII inhibitors

Domenico Prisco, Irene Mattioli, Raffaele De Caterina, Alessandra Bettiol

https://doi.org/10.4081/btvb.2023.76

2731

PDF: 1113

The subtle red line between combating and resolving inflammation in the cardiovascular disease, a “silent sniper”

Ciarán Kennedy, Luke J. Conroy, Braden Millar, Monica de Gaetano

https://doi.org/10.4081/btvb.2025.187

1259

PDF: 318

The use of creatine and the development of deep vein thrombosis. A scoping review

Kartik Akkihal, Thomas Varkey, James Kelbert

https://doi.org/10.4081/btvb.2024.142

8071

PDF: 472

Supplementary: 155

The von Willebrand factor-ADAMTS-13 axis: a two-faced Janus in bleeding and thrombosis

Stefano Lancellotti, Monica Sacco, Maira Tardugno, Antonietta Ferretti, Raimondo De Cristofaro

https://doi.org/10.4081/btvb.2022.11

2343

PDF: 473

Tumor necrosis factor superfamily in multiple sclerosis: from pathology to therapeutic implications

Federica Azzolini, Antonio Bruno, Ettore Dolcetti, Diego Centonze, Fabio Buttari

https://doi.org/10.4081/btvb.2023.66

1306

PDF: 374

Unveiling the “common soil” of cardiovascular disease and cancer

Licia Iacoviello, Maria Benedetta Donati

https://doi.org/10.4081/btvb.2025.167

1272

PDF: 341

Vasculopathy: a possible factor affecting hereditary angioedema

Anna Laura Colia, Alessandra Ranaldi, Rosa Santacroce, Giovanna D'Andrea, Angela Bruna Maffione, Maurizio Margaglione, Maria D'Apolito

https://doi.org/10.4081/btvb.2025.152

1003

pdf: 306

Venous thromboembolism prophylaxis in orthopedic surgery: a narrative review

Sarah Gallitto, Thomas C. Varkey, Jacob Lahti

https://doi.org/10.4081/btvb.2024.131

2907

PDF: 374

Reviews

All Items

A re-appraisal of thrombogenesis in COVID-19, seen as a multiple "Complex system"

Addressing some challenges of congenital fibrinogen disorders in 2023 and beyond

An ecological alliance against air pollution and cardiovascular disease

Anticoagulation in obese patients: challenges and strategies

Antithrombotic therapy in idiopathic infertility

Artificial intelligence and machine learning in hemostasis and thrombosis

Aspirin or low-molecular weight heparin for thromboprophylaxis after a fracture? That is the question

Bioequivalence of von Willebrand factor-containing concentrates: implications for the choice in patients with von Willebrand disease. A position paper from the Italian Association of Hemophilia Centers

Blood platelets, prostaglandins and aspirin: a historical and personal rereading

Cardiovascular risk in hormone replacement therapy

Distal deep vein thrombosis: is there a way out of this dark forest?

Factor XI inhibitors in adjunct to antiplatelet therapy: the ultimate dual-pathway inhibition?

From rare to aware: confronting Lemierre syndrome

Hemostasis and the kidney: an unforeseen initial opportunity to create a small research group that grew into an institute

Inflammation, platelets and diabetes

New perspectives for prevention of the post-thrombotic syndrome

Polycythemia vera and management of the thrombotic risk: an update

Recent advances in classic heparin-induced thrombocytopenia (HIT), autoimmune HIT, spontaneous HIT, and vaccine-induced immune thrombotic thrombocytopenia

Role of platelet autophagy in cardiovascular diseases

Stroke in women: anticoagulation in a complicated puzzle

The amazing genetic complexity of anucleated platelets

The changing landscape of treatment for acquired hemophilia A

The evolution of hemostasis genetics: from monogenic disorders to complex traits. A historical perspective

The evolving landscape of gene therapy for congenital severe hemophilia: a 2024 state of the art

The key to fibrinolysis and thrombolysis

The new era of anticoagulation: factor XI and XII inhibitors

The subtle red line between combating and resolving inflammation in the cardiovascular disease, a “silent sniper”

The use of creatine and the development of deep vein thrombosis. A scoping review

The von Willebrand factor-ADAMTS-13 axis: a two-faced Janus in bleeding and thrombosis

Tumor necrosis factor superfamily in multiple sclerosis: from pathology to therapeutic implications

Unveiling the “common soil” of cardiovascular disease and cancer

Vasculopathy: a possible factor affecting hereditary angioedema

Venous thromboembolism prophylaxis in orthopedic surgery: a narrative review

authors

reviewers

Categories

indexing

Keywords